Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

TB Screening Recommended for High-Risk Healthcare Workers Only

By LabMedica International staff writers
Posted on 08 Aug 2017
Routine screening for and treatment of latent tuberculosis (TB) infection has traditionally been an important part of TB prevention in Canadian and US healthcare institutions, but recent data have called into question its cost effectiveness. More...
A new study has found that the current strategy of annual screening of is ineffectively expensive, suggesting that a switch to screening only high-risk healthcare workers is needed.

“The background rate of TB in North American communities is much lower today than it was 25 years ago when there were epidemics of TB in cities across the United States. As such, the risk of healthcare workers being exposed and infected at work is also much lower,’’ said study corresponding author Prof. Dr. Kevin Schwartzman, of McGill University Health Centre (MUHC; Montreal, Canada), Research Institute of MUHC, and McGill International TB Centre, “Our results suggest the annual TB screening protocol should be changed to reflect more accurately the epidemiology of TB in North America and potentially in other high-income countries, such as those in Northern Europe.’’

The researchers used published data to simulate the experience of a cohort of 1,000 workers who received a baseline negative test after hiring – considering duties, tuberculosis exposure, testing and treatment. They compared the cost-effectiveness of 3 screening strategies: annual screening (for all workers with significant patient contact), targeted screening (regular screening of only the highest risk workers), and post-exposure screening (screening only after identified exposure). They considered two tests to diagnose TB infection: the tuberculin skin test (TST) and the newer QuantiFERON-TB-Gold In-Tube (QFT) test from Qiagen. The QFT test was found to be more expensive to use than the TST test, with limited or no additional benefits.

“We projected costs, morbidity, quality-adjusted survival and mortality over 20 years after hiring. One of the most striking findings was that the current annual screening strategy costs over $1.7 million to prevent one additional case of active TB in a healthcare worker, when compared to a more targeted screening strategy, which in turn costs around $400,000 more per additional case when compared to the post-exposure screening protocol,’’ said study first-author Guillaume Mullie, medical student at McGill University, “The costs of current practices are quite significant for the healthcare system, and reconsideration of this long-standing recommendation may be warranted.’’ Dr. Schwartzman added, “The more you test healthcare workers without true exposure, the more likely it is that when you do find a positive test it will be a false positive because the tests are never perfect.”

According to the researchers, healthcare workers should not be called back routinely every year for testing just because that is the protocol. Instead, only workers at a particularly high-risk (for example respiratory therapists performing bronchoscopies, or microbiology laboratory workers) should continue to be tested regularly regardless of stated exposure. Other workers should be evaluated only after exposure to a contagious patient.

“Resources currently allocated to routine TB testing for healthcare workers in North America could instead be used to increase access to prevention, treatment, and testing infrastructure and support in communities that are at higher risk of developing TB disease, such as homeless, foreign-born, and indigenous people,” said Dr. Schwartzman.

The study, by Mullie GA et al, was published May 17, 2017, in the journal BMC Medicine.

Related Links:
McGill University Health Centre
Research Institute of MUHC
McGill International TB Centre


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.